Skip to main content

Table 4 Characteristics of 28 patients suffering re-sting reactions during or after VIT

From: Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom

Patient no.

Age1(y)

Sex(m/f)

BST(μg/L)

Allergy testing

VIT duration (y)

Post-VIT observation time (y)

No. of stings4

Field sting5

Severity of reactions (grade I-III)

    

Before VIT

End of VIT

       
    

IgE2bee

IgE2vesp

ID3bee

ID3vesp

IgE2bee

IgE2vesp

ID3bee

ID3vesp

    

Before VIT

During VIT

After VIT

Patients receiving honey bee VIT

     

1

43

m

n.d.

3

0

n.d.

neg

3

0

0.1

neg

5

14

>5

bee

II

-

I

2

20

m

n.d.

6

1

0.001

1

2

0

0.1

neg

4

9

1

bee

II

LR

I

3

39

f

n.d.

3

1

0.01

neg

1

0

1

1

3

10

3

bee

II

LR

I

4

53

f

n.d.

2

0

0.001

1

2

0

0.01

0.1

3

14

1

bee

II

I

-

5

53

m

n.d.

6

4

0.001

0.01

3

0

0.001

0.1

5

8

1

vesp

III

-

I

6

37

f

n.d.

3

2

0.1

neg

2

1

0.1

neg

3

2

1

bee

II

-

I

7

26

m

n.d.

3

2

0.01

0.01

2

1

0.01

0.1

6

13

5

u

III

-

II

8

11

m

n.d.

3

4

0.001

0.1

3

3

0.1

0.01

5

2

4

u

II

II

LR

9

28

f

n.d.

4

2

0.001

0.01

2

0

0.1

0.1

5

12

2

bee

III

-

II

Patients receiving Vespula VIT

10

18

f

n.d.

0

3

neg

0.01

0

2

neg

0.01

5

12

2

vesp

II

LR

I

11

50

f

7.63

0

2

neg

0.1

0

3

neg

1

5

2

2

vesp

II

LR

II

12

39

f

n.d.

0

2

neg

0.1

0

0

neg

0.01

3

8

6

vesp

III

-

I

13

21

m

4,97

0

3

neg

0.001

0

2

neg

0.1

3

8

3

vesp

II

-

II

14

47

f

n.d.

0

2

neg

0.1

0

2

neg

1

5

4

1

vesp

III

-

II

15

51

m

n.d.

0

3

neg

0.001

0

0

neg

0.1

3

11

1

vesp

III

-

I

16

48

f

n.d.

0

2

neg

0.01

0

2

neg

0.1

5

4

1

u

I

-

II

17

30

f

n.d.

0

3

neg

0.1

0

0

neg

1

3

10

1

u

II

I

-

18

56

f

n.d.

0

5

neg

0.001

0

3

neg

0.1

5

7

1

vesp

II

-

I

19

32

m

n.d.

1

1

neg

0.1

0

0

1

0.1

4

13

3

vesp

III

LR

II

20

54

m

6.69

3

2

1

0.1

2

2

neg

0.1

3

13

4

vesp

III

-

III

21

53

m

110,0

3

3

0.1

0.01

0

1

1

1

3

11

3

u

III

-

II

22

45

m

n.d.

2

2

1

0.01

1

3

neg

0.1

5

4

3

vesp

III

II

-

23

30

m

n.d.

3

4

0.1

0.001

0

1

1

0.1

3

9

2

vesp

I

-

III

24

55

f

n.d.

2

2

0.01

0.01

0

0

1

0.1

4

8

2

vesp

II

I

LR

25

40

m

n.d.

2

3

0.01

0.001

n.d.

n.d.

n.d.

n.d.

3

14

1

u

III

-

I

26

37

m

n.d.

2

3

0.01

0.01

2

2

0.1

1

3

9

3

u

III

-

II

27

39

f

n.d.

2

5

1

0.001

1

2

1

0.1

6

9

2

vesp

II

-

II

28

46

f

n.d.

2

2

neg

n.d.

2

2

1

0.1

3

13

3

vesp

I

-

II

  1. 1Age at the time of VIT initiation, 2figures refer to semi-quantitative serological classes, 3figures refer to intradermal test endpoint concentrations (μg/mL), 4number of Hymenoptera stings after VIT initiation, 5Hymenoptera sting eliciting systemic reaction during or after VIT.
  2. Abbreviations: bee honey bee, BST baseline serum tryptase, ID intradermal skin test, LR local reaction, n.d. not determined, neg negative, vesp, Vespula species, VIT venom immunotherapy, u unknown.
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us